Market closed
Anavex/$AVXL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Anavex
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Ticker
$AVXL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
40
Website
Anavex Metrics
BasicAdvanced
$776M
Market cap
-
P/E ratio
-$0.50
EPS
0.63
Beta
-
Dividend rate
Price and volume
Market cap
$776M
Beta
0.63
52-week high
$10.45
52-week low
$3.25
Average daily volume
1.1M
Financial strength
Current ratio
12.041
Quick ratio
11.951
Management effectiveness
Return on assets (TTM)
-20.43%
Return on equity (TTM)
-30.03%
Valuation
Price to book
5.98
Price to tangible book (TTM)
5.98
Price to free cash flow (TTM)
-25.241
Growth
Earnings per share change (TTM)
-23.47%
3-year earnings per share growth (CAGR)
0.99%
What the Analysts think about Anavex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Anavex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Anavex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Anavex News
AllArticlesVideos
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
Seeking Alpha·7 days ago
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024
GlobeNewsWire·2 weeks ago
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $776M as of November 13, 2024.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of November 13, 2024.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of November 13, 2024.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.